• Source: Scopus
  • Calculated based on no. of publications stored in Pure and citations from Scopus
1990 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Area of Expertise

G protein-coupled receptors remain the single largest group of “druggable” proteins that continue to find tremendous utility in academic lab and pharmaceutical company drug-discovery programs. In 1994, Siderovski was the first to report the sequencing of a “Regulator of G protein Signaling” (RGS protein): 'G0/G1-switch gene-8' or G0S8 (subsequently renamed RGS2). Before the discovery of RGS proteins, the duration of heterotrimeric G-protein signaling was thought to be controlled solely by the intrinsic GTP hydrolysis rate of the G-alpha subunit. What Siderovski originally identified as the G0S8-homology ("GH") domain in proteins from several eukaryotic genomes (human, Drosophila melanogaster, Caenorhabditis elegans, Saccharomyces cerevisiae) is now known as the "RGS domain", a 130 amino-acid domain that contacts G-alpha switch regions to stabilize the transition state, thus accelerating GTP hydrolysis (i.e., RGS proteins act as GTPase-accelerating proteins or "GAPs" for G-alpha-GTP). Discovery of a superfamily of RGS domain-containing proteins that negatively regulate G-alpha-dependent signaling resolved a prior paradox that GPCR-stimulated signals are seen to terminate much faster in vivo than predicted from the slow GTP hydrolysis rates exhibited by purified G-alpha subunits in vitro. RGS proteins are now considered key desensitizers of heterotrimeric G protein signaling and, as such, as new drug discovery targets.

Fingerprint

Dive into the research topics where David Siderovski is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.
If you made any changes in Pure these will be visible here soon.